- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04278937
Antenatal Azithromycin to Prevent Preterm Birth in Pregnant Women With Vaginal Cerclage
Antenatal Azithromycin to Prevent Preterm Birth in Pregnant Women With Vaginal Cerclage. A Randomized Controlled Trial
Study Overview
Detailed Description
Study procedures and interventions:
- After approval of study protocol, pregnant women who underwent vaginal cerclage at Ain Shams University Maternity Hospital will be enrolled into the study according to inclusion and exclusion criteria.
- Eligible patients will be randomized using a computer-generated sequence 1:1 either to the Azithromycin group or to non-Azithromycin group.
Randomization: Will be done using computer generated randomization sheet using MedCalc© version 13.
Allocation and Concealment: Will be done by use of sealed opaque envelopes that will be given to a third party (nurse) who will assign the women to study arms. Each woman will be invited to pull out an envelope. According to the number inside her envelope, women will be allocated to either group 1 or group 2 according to a computer- generated random list.
3. Intervention:
- st group (Azithromycin group): 25 women will receive 500mg Azithromycin (Zithrokan®, Hikma, Egypt) one tablet orally twice daily for three days in 3 courses at 14wk, 24wk and 32wk in addition to routine usual antenatal care.
- nd group (non-Azithromycin group): 25 women will receive routine antenatal care without antibiotic prophylaxis after cerclage.
4. Follow up: Through antenatal care at 4 weeks interval till 28 weeks gestational age then at 2 weeks interval till delivery.
History: Routine ANC history with special comment on history of infection as (pain, bleeding, offensive discharge).
Examination: Routine ANC examination with special comment on signs of infection (fever, tachycardia).
Investigation: As scheduled routine labs (CBC, Urine analysis, etc) and ultrasound.
5. Data collection and recording case record form: The data will be collected in a case record form (age, parity, body mass index (BMI), mode of the delivery, previous adverse perinatal outcome, gestational age at time of delivery, birth weight, NICU admission, still birth, miscarriage, antepartum hemorrhage, hospital stay, postpartum pyrexia, ICU admission, need for blood transfusion.
To decrease risk of bias, the observer collecting the data will be blinded as regards whether they are azithromycin group or non-azithromycin group.
Statistical analysis:
The collected data will be revised, coded, tabulated and introduced to a PC using Statistical package for Social Science (SPSS 20.0.1 for windows; SPSS Inc, Chicago, IL, 2001). Quantitative variables are expressed as mean and SD, or Median and Interquartile range (IQR) according to distribution of data. Qualitative variables are expressed as frequencies and percentages. Student t test and Mann Whitney Test will be used to compare a continuous variable between two study groups. Chi square test will be used to examine the relationship between Categorical variables. A P-value< 0.05 was considered statistically significant.
Ethical and Safety Consideration:
This study will be done after approval of the ethical committee of the department of obstetrics and gynecology, faculty of medicine, Ain Shams University. Informed consent will be taken from all participants before recruitment in the study, and after explaining the purpose and procedures of the study. The investigator will obtain the written, signed informed consent of each subject prior to performing any study specific procedures on the subject. The investigator will retain the original signed informed consent form. All data will be collected confidentially. Women with vaginal cerclage will be counseled about the side effects associated with cerclage and Azithromycin. The study will be based on the investigator self-funding.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- Ain Shams Maternity Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Gestational age (14-34 weeks).
- Pregnant women who underwent vaginal cerclage (either history- based or ultrasound based vaginal cerclage)
History based cerclage:
- History of one or more second-trimester pregnancy losses related to painless cervical dilatation and in absence of labor or abruptio placentae; OR
- Prior cerclage due to painless cervical dilation in the second trimester
Ultrasound based cerclage:
Current singleton pregnancy, prior spontaneous preterm birth at less than 34 weeks of gestation, and short cervical length (less than 25 mm) before 24 weeks of gestation
Exclusion Criteria:
- Multiple pregnancy.
- Current or past history of medical diseases (Diabetes Milletus, Hypertension, Systemic Lupus Erythematosus, Cardiac diseases, etc ).
- Adverse perinatal outcome due to abdominal trauma.
- Structural fetal anomalies detected during anomaly scan.
- Allergy to Azithromycin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Azithromycin group
women will receive 500mg Azithromycin (Zithrokan®, Hikma, Egypt) one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks in addition to routine usual antenatal care.
|
one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks
Other Names:
|
No Intervention: Control group
women will receive routine antenatal care without antibiotic prophylaxis after cerclage.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gestational age at time of delivery
Time Frame: At time of delivery
|
the gestational age measured in weeks
|
At time of delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Birth weight
Time Frame: At time of delivery
|
the weight of the baby measured in grams
|
At time of delivery
|
Neonatal complications
Time Frame: At time of delivery and in the first postpartum week
|
complications occurring in the neonate (still birth / neonatal intensive care unit admission).
|
At time of delivery and in the first postpartum week
|
Maternal complications
Time Frame: At time of delivery and in the first postpartum week
|
complications occurring in the mother (antepartum hemorrhage, postpartum pyrexia >38 Celsius, need for blood transfusion, hospital stay, ICU admission).
|
At time of delivery and in the first postpartum week
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Sherif A Ashoush, MD, Professor
- Study Chair: Hassan A Bayoumy, MD, Professor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FMASU 1304/2019
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preterm Birth
-
e-Bio CorpRecruitingPreterm Labor | PreTerm Birth | Preterm Labor With Delivery NosUnited States
-
Thomas Jefferson UniversityCompleted
-
Federico II UniversityRecruiting
-
University of OxfordShoklo Malaria Research UnitCompleted
-
Chelsea and Westminster NHS Foundation TrustSPD Development Company Limited; Borne CharityRecruitingPreterm Birth | Preterm Labor | Preterm Birth Complication | Preterm Premature Rupture of Membrane | Preterm PregnancyUnited Kingdom
-
PreTeL, IncDuke University; University of RochesterRecruitingPreterm Birth | Threatened Preterm Labor | PreTerm LaborUnited States
-
Cairo UniversityCompleted
-
University of OklahomaCompletedPreTerm Birth | PreTerm NeonateUnited States
-
Eunice Kennedy Shriver National Institute of Child...CompletedPregnancy | Preterm Birth | Preterm LaborUnited States
-
University Hospital Inselspital, BerneAmniSure International LLCCompletedPreterm Birth | Preterm LabourSwitzerland
Clinical Trials on Azithromycin Tablets
-
SandozCompleted
-
SandozCompleted
-
CF Therapeutics Development Network Coordinating...Cystic Fibrosis FoundationCompletedCystic FibrosisUnited States, Canada
-
Mylan Pharmaceuticals IncCompleted
-
Mylan Pharmaceuticals IncCompleted
-
Tel-Aviv Sourasky Medical CenterTel Aviv UniversityUnknownFamilial Adenomatous PolyposisIsrael
-
Ain Shams UniversityCompleted
-
Lihir Medical CentreUniversity of Washington; World Health Organization; Barcelona Institute for... and other collaboratorsCompletedYawsPapua New Guinea
-
University of TaubateFundação de Amparo à Pesquisa do Estado de São PauloCompletedPeriodontitisBrazil
-
Rigshospitalet, DenmarkCystic Fibrosis FoundationCompleted